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Abstract 
Review on t(6;11)(q21;q23) KMT2A/FOXO3 in 
acute promyelocytic leukaemia, with data on clinics, 
and the genes involved. 
Clinics and pathology 
Disease 
Acute myeloid leukemia (AML), acute 
lymphoblastic leukemia (ALL), and other 
lyphoproliferative diseases. 
Epidemiology 
Eleven cases of t(6;11)(q21;q23) have been 
described so far: 5 cases of AML (2 M5a-AML, 1 
M2-AML, 2 AML not otherwise specified (NOS)), 
3 cases of pediatric ALL, 1 case of acute 
undifferentiated leukemia (AUL), 1 case of 
prolymphocytic leukemia, and 1 case of peripheral 
T-cell lymphoma (Heim et al., 1992; Hillion et al., 
1997; Bernard et al., 1998; Wong et al., 1999; Stark 
et al., 2004; Andersen et al., 2005; Helbig et al., 
2006; Zuna et al., 2009; Meyer et al., 2013; Parkin et 
al., 2013). However, the formation of a hybrid 
KMT2A/FOXO3 was ascertained only in 5 of these 
11 cases, namely in the M2-AML, in the AUL, and 
in the 3 pediatric ALLs (Hillion et al., 1997; Bernard 
et al., 1998; Zuna et al., 2009; Meyer et al., 2013). 
The involvement of KMT2A was ascertained in 
another case (an AML-NOS, Stark et al., 2004), 
while other cases may have other gene 
rearrangements instead. Five of the 5 cases with a 
proved KMT2A/FOXO3 hybrid gene were therapy-
related leukemias: the M2-AML occured 2 years 
after treatment for Hodgkin disease, the AUL also 
occured after Hodgkin disease, a pro-B ALL occured 
2.5 years after treatment for a M3-AML with the 
classical t(15;17), and the 2 other ALLs were also 
therapy-induced leukemia cases. Also, another case, 
a M5a occured after radiotherapy for carcinoma of 
the larynx. There was 6 male and 5 female patients, 
Median age was 40-45 years (range: ? (pediatric 
case) - 80). The 5 patients with proved 
KMT2A/FOXO3 hybrid gene were: a boy and a girl, 
a F/15 yrs,  M/22 yrs, and a M/40 yrs. 
Prognosis 
Scarce data (34months+ survival in one of the ALLs 
with proved KMT2A/FOXO3 hybrid gene). 
Cytogenetics 
Cytogenetics morphological 
The t(6;11)(q21;q23) is the sole abnormality in 5 of 
9 cases, and in 2 of 3 cases with proved 
KMT2A/FOXO3 hybrid gene. 
Genes involved and 
proteins 
FOXO3 
Location 
6q21 
Protein 
673 amino acids. FOXO3 has both a NLS (nuclear 
localization signal, amino acids 249-251, 269-271) 
and a NES (nuclear export signal, amino acids 386-
396), possess a forkhead domain (DNA-binding 
domain, amino acids 148-257) and a transactivation 
domain (amino acids 1251-673). 
